5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS Clinical Trial
Official title:
De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal
Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").
A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group). ;